Xindi Wang

654 total citations
39 papers, 405 citations indexed

About

Xindi Wang is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, Xindi Wang has authored 39 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Xindi Wang's work include CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (6 papers) and Ophthalmology and Visual Impairment Studies (3 papers). Xindi Wang is often cited by papers focused on CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (6 papers) and Ophthalmology and Visual Impairment Studies (3 papers). Xindi Wang collaborates with scholars based in China, Canada and United States. Xindi Wang's co-authors include Peng Zhang, Wenjing Luo, Guanhua Su, Wei Yi, Yifan Zhang, Bin Xu, Shi Chen, Nan Shen, Chenggong Li and Heng Mei and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Advanced Functional Materials.

In The Last Decade

Xindi Wang

35 papers receiving 400 citations

Peers

Xindi Wang
Junjie Lu China
Jiaying Cao China
Yun-Ting Hsu Taiwan
W. F. Liang Taiwan
Masayuki Fukuzawa Japan
Michael J. Flaig Germany
Jonathan Bowling United Kingdom
Jae Jun Park South Korea
Lukas Koch Austria
Sungtae Park United States
Junjie Lu China
Xindi Wang
Citations per year, relative to Xindi Wang Xindi Wang (= 1×) peers Junjie Lu

Countries citing papers authored by Xindi Wang

Since Specialization
Citations

This map shows the geographic impact of Xindi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xindi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xindi Wang more than expected).

Fields of papers citing papers by Xindi Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xindi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xindi Wang. The network helps show where Xindi Wang may publish in the future.

Co-authorship network of co-authors of Xindi Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Xindi Wang. A scholar is included among the top collaborators of Xindi Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xindi Wang. Xindi Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Zhihan, Weijun Luo, Yun Jin Kang, et al.. (2025). Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 216. 104969–104969.
3.
Luo, Lei, Xindi Wang, Yu Zhang, et al.. (2025). Ray tracing-guided LASIK for high myopia and astigmatism: Initial clinical outcomes. Photodiagnosis and Photodynamic Therapy. 55. 104715–104715. 3 indexed citations
4.
5.
Wang, Xindi, et al.. (2025). Predictability of central corneal stromal thickness reduction in InnovEyes ablation profile: A retrospective study. Photodiagnosis and Photodynamic Therapy. 53. 104570–104570. 2 indexed citations
6.
7.
Li, Yingying, Jiachen Liu, Lijuan Zhou, et al.. (2025). Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL. Thrombosis Research. 256. 109527–109527.
8.
Zhao, Penghui, Xindi Wang, Yi Zhang, et al.. (2024). Diffusion‐UDA: Diffusion‐based unsupervised domain adaptation for submersible fault diagnosis. Electronics Letters. 60(3). 4 indexed citations
9.
Luo, Wenjing, Yinqiang Zhang, Chenggong Li, et al.. (2024). BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. Blood. 144(Supplement 1). 6546–6546. 1 indexed citations
10.
Luo, Wenjing, Chenggong Li, Lu Tang, et al.. (2024). Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma. Blood. 144(Supplement 1). 3420–3420. 2 indexed citations
11.
Wang, Xindi, et al.. (2024). Sex differences in diabetes‑induced hepatic and renal damage. Experimental and Therapeutic Medicine. 27(4). 148–148. 5 indexed citations
12.
Wang, Minghuan, et al.. (2023). Micro-milling microstructures in air-shielding ultrasonic assisted electrochemical machining. Journal of Manufacturing Processes. 97. 171–184. 18 indexed citations
13.
Zhang, Yinqiang, Chenggong Li, Mengyi Du, et al.. (2023). Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer Journal. 13(1). 61–61. 52 indexed citations
14.
Chen, Zhaozhao, Lu Tang, Lili Luo, et al.. (2023). Enhancing the Treatment of Uncontrolled Inflammation through the Targeted Delivery of TPCA-1-Loaded Nanoparticles. Pharmaceutics. 15(10). 2435–2435. 3 indexed citations
15.
Wang, Hongyan, Bin Yi, Yadan Wang, et al.. (2023). Cerebellar ataxia with anti-mGluR1 auto-antibody in a pediatric patient: A case report. Journal of Neuroimmunology. 378. 578082–578082. 3 indexed citations
16.
Wang, Xindi, Chenbo Ding, & Huabing Li. (2023). The crosstalk between enteric nervous system and immune system in intestinal development, homeostasis and diseases. Science China Life Sciences. 67(1). 41–50. 12 indexed citations
17.
Luo, Wenjing, Chenggong Li, Jianghua Wu, et al.. (2023). Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma. Cytotherapy. 25(7). 739–749. 14 indexed citations
18.
Li, Chenggong, Jia Xu, Wenjing Luo, et al.. (2023). Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 38(1). 149–159. 45 indexed citations
19.
Zheng, Yongqiang, Ying Chen, Xindi Wang, et al.. (2021). Fatal Infections Among Cancer Patients: A Population-Based Study in the United States. Infectious Diseases and Therapy. 10(2). 871–895. 56 indexed citations
20.
Li, Xingjun, Hongfang Jin, Cheng Huang, et al.. (2017). Clinical features, treatment and prognosis of neuroblastoma with bone metastasis in children. Zhonghua shiyong erke linchuang zazhi. 32(3). 182–186. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junjie Lu Breakdown of academic impact, for papers by Jiaying Cao Breakdown of academic impact, for papers by Yun-Ting Hsu Breakdown of academic impact, for papers by W. F. Liang Breakdown of academic impact, for papers by Masayuki Fukuzawa Breakdown of academic impact, for papers by Michael J. Flaig Breakdown of academic impact, for papers by Jonathan Bowling Breakdown of academic impact, for papers by Jae Jun Park Breakdown of academic impact, for papers by Lukas Koch Breakdown of academic impact, for papers by Sungtae Park
Rankless by CCL
2026